Trial Profile
Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Florbetapir F 18 (Primary)
- Indications Amyloidosis
- Focus Diagnostic use
- 02 Jan 2024 Status changed from recruiting to completed.
- 14 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.
- 14 Jan 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2023.